Cephalon Inc. / CIMA Labs Inc.

Breakthrough Cancer Pain (BTCP)

Disease Overview

Breakthrough cancer pain refers to transient severe pain flares that occur despite scheduled opioid therapy in advanced cancer patients. Fast-onset transmucosal fentanyl formulations were developed because oral opioids cannot match the rapid onset and short duration profile required to manage these episodes.

Competitive Landscape

This entry represents the August 9, 2004 closing event of the same Cephalon-CIMA transaction first signed in November 2003, gated on FTC consent. At close, Cephalon controlled both Actiq (the dominant marketed BTCP fentanyl lozenge) and the late-stage OraVescent fentanyl buccal tablet (later branded Fentora, approved September 2006). The structural remedy required Cephalon to license a fully paid-up, irrevocable generic Actiq right to Barr Laboratories — a notable FTC intervention in pharma at the time, structured to restore brand-to-generic competition that the deal would have eliminated. Post-close, Fentora's 2006 launch lifted Cephalon's BTCP franchise revenue trajectory, partially offsetting Actiq's anticipated generic erosion. The category was subsequently expanded by Onsolis (BDSI/Meda), Subsys (Insys), Lazanda, and Abstral, and was later compressed by the broader REMS framework imposed on transmucosal fentanyl products and by the post-2010 opioid policy environment.